12. Where—U.K.
(a)the manufacturing authorisation relates to the assembly of an investigational medicinal product [F1or EAMS medicinal product];
(b)that investigational medicinal product [F1or EAMS medicinal product] is not manufactured by the holder of the authorisation; and
(c)particulars as to the name and address of the manufacturer of, or of the person who imports, that investigational medicinal product [F1or EAMS medicinal product] had been given by the holder of the authorisation to the licensing authority,
the holder of the authorisation shall forthwith notify the licensing authority in writing of any changes in such particulars.
Textual Amendments
F1Words in Sch. 7 Pt. 2 para. 12 inserted (15.4.2022) by The Human Medicines (Amendments Relating to the Early Access to Medicines Scheme) Regulations 2022 (S.I. 2022/352), regs. 1(2), 18(2)(f) (with reg. 19)